Padma Malyala

Vice President, Formulation and Analytical Development at Verve Therapeutics

Padma Malyala is Vice President, Formulation and Analytical Development at Verve Therapeutics. She has nearly 20 years’ experience in formulation and characterization of complex biotherapeutics at Novartis, GSK and MedImmune-AstraZeneca. Most recently, Ms. Malyala served as head of the formulation and characterization group for Biologics at Novartis Institute for Biomedical Research (NIBR), where she was responsible for de-risking the development process and transition well defined robust drug products to the clinic. She was also a key member of due diligence teams to strengthen the drug product science, as well as the immuno- oncology portfolio. As global head, pharmaceutical sciences in technical R&D at GSK, she managed technology transfer of the RNA-LNP platform technology to development, using QbD principles. Previously, Ms. Malyala served as group leader, formulations at MedImmune – AstraZeneca and as global head-pharmaceutical sciences at Novartis Vaccines. She is the author of multiple patents, publications and book chapters in the field of formulation, characterization and delivery systems. Ms. Malyala received both her B.S. in Pharmaceutical Sciences and M.S. in Pharmaceutical Chemistry (Gold Medalist) from Andhra University in India.